MannKind Corporation reported $394M of revenue over the trailing twelve months, +30% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $394M (to Q2 2026). Net income: −$44M, trailing twelve months to Q2 2026. Free cash flow: −$18M, trailing twelve months to Q2 2026. Operating margin: 3.5%, trailing twelve months to Q2 2026.

MNKDMannKind Corporation

Healthcare

$3.29-39% 1Y

$3.29

$2.2852 weeks$6.21

MNKD as reported

MannKind Corporation reported $394M of revenue over the trailing twelve months, +30% on the year before. 11 reported series are charted on this page, each one as filed.

$394M

Revenue, trailing twelve months · to Q2 2026 · +30% against the twelve months before

Net income: −$44M
Net income · −233% year on year · trailing twelve months to Q2 2026
Free cash flow: −$18M
Free cash flow · −163% year on year · trailing twelve months to Q2 2026
Operating margin: 3.5%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for MNKD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$394M	+30%	Q2 2026
Net income	−$44M	−233%	Q2 2026
EPS	−$0.13	−218%	Q2 2026
Gross margin	90%	n/a	Q2 2026
Operating margin	3.5%	n/a	Q2 2026
Net margin	−10%	n/a	Q2 2026
ROE	7.0%	n/a	Q2 2026
ROA	−0.63%	n/a	Q2 2026
ROIC	2.0%	n/a	Q2 2026
Free cash flow	−$18M	−163%	Q2 2026
P/E	105	n/a	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.